NGL Fine-Chem Limited Stock Price Today (NSE: NGLFINE)
Fundamental Score
NGL Fine-Chem Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
NGL Fine-Chem Limited share price today is ₹2673.80, up +3.56% on NSE/BSE as of 16 September 2026. NGL Fine-Chem Limited (NGLFINE) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.65K (Cr). The 52-week high for NGLFINE share price is ₹3602.00 and the 52-week low is ₹1271.00. At a P/E ratio of 28.88x, NGLFINE is currently trading below its industry average P/E of 34.89x. 0
NGL Fine-Chem Limited Share Price Chart — NSE/BSE Historical Performance
NGL Fine-Chem Limited share price chart: -18.69% return over the past month. 52-week high ₹3602.00, 52-week low ₹1271.00.
NGL Fine-Chem Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2543.20 | ₹2738.90 | ₹2505.10 | ₹2673.80 | 11.72K (Cr) | |
| ₹2657.20 | ₹2690.90 | ₹2541.50 | ₹2581.80 | 7.74K (Cr) | |
| ₹2723.50 | ₹2723.50 | ₹2578.00 | ₹2657.20 | 8.52K (Cr) | |
| ₹2776.30 | ₹2790.40 | ₹2700.00 | ₹2725.70 | 4.06K (Cr) | |
| ₹2811.60 | ₹2834.20 | ₹2750.00 | ₹2758.30 | 2.47K (Cr) | |
| ₹2887.30 | ₹2911.80 | ₹2736.60 | ₹2811.60 | 9.48K (Cr) | |
| ₹2868.10 | ₹2907.90 | ₹2815.20 | ₹2873.00 | 7.06K (Cr) | |
| ₹2940.00 | ₹2981.90 | ₹2890.50 | ₹2907.50 | 7.11K (Cr) | |
| ₹2719.90 | ₹2999.80 | ₹2676.00 | ₹2940.80 | 69.06K (Cr) | |
| ₹2664.30 | ₹2745.00 | ₹2575.10 | ₹2688.70 | 11.22K (Cr) |
NGL Fine-Chem Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2640.00 | ₹2999.80 | ₹2505.10 | ₹2673.80 | +1.28% | |
| ₹3299.00 | ₹3602.00 | ₹2620.00 | ₹2649.50 | -19.69% | |
| ₹3062.00 | ₹3349.00 | ₹2900.00 | ₹3260.30 | +6.48% | |
| ₹2834.40 | ₹3232.00 | ₹2550.00 | ₹3107.50 | +9.64% | |
| ₹2202.00 | ₹3005.00 | ₹2106.10 | ₹2785.10 | +26.48% | |
| ₹2100.00 | ₹2495.00 | ₹2021.30 | ₹2214.50 | +5.45% | |
| ₹2232.00 | ₹2575.00 | ₹1998.10 | ₹2057.10 | -7.84% | |
| ₹1730.00 | ₹2575.00 | ₹1659.20 | ₹2301.20 | +33.02% | |
| ₹1413.20 | ₹1800.00 | ₹1357.00 | ₹1677.30 | +18.69% | |
| ₹1325.20 | ₹1433.90 | ₹1271.00 | ₹1406.20 | +6.11% | |
| ₹1511.60 | ₹1650.00 | ₹1294.70 | ₹1340.90 | -11.29% | |
| ₹1419.30 | ₹1563.80 | ₹1410.00 | ₹1504.30 | +5.99% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
NGL Fine-Chem Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
NGL Fine-Chem Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NGLFINE across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Excellent ROCE Performance (19.11%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (16.71%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (2282.69%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (33.57%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (13.62% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Interest Coverage (15.18x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 1.98)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (72.74%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (0.00%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
High Price-to-Book Ratio (5.85x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Weak Earnings Growth (-5.58% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-5.58% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Negative Free Cash Flow (₹-188.21 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.03%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
NGL Fine-Chem Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare NGL Fine-Chem Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
NGL Fine-Chem LimitedNGL Fine-Chem L...Selected✓ NGLFINE • 524774 | 49.3/100 | ₹2673.80₹2674 | ₹1651.87₹1651.87 | 28.88Average 28.9 Average | 0.00%Poor 0.00% Poor | 19.11%Good 19.11% Good | 0.33Excellent 0.3 Excellent | -5.58%Poor -5.58% Poor | 13.62%Good 13.62% Good | 0.06% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1869.10₹1869 | ₹448453.16₹448453.16 | 37.09Average 37.1 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9460.50₹9461 | ₹250703.25₹250703.25 | 85.84Average 85.8 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4942.00₹4942 | ₹167266.93₹167266.93 | 78.95Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1130.60₹1131 | ₹112833.88₹112833.88 | 25.20Average 25.2 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1370.70₹1371 | ₹110732.00₹110732.00 | 32.84Average 32.8 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1934.30₹1934 | ₹104500.56₹104500.56 | 95.47Average 95.5 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1675.90₹1676 | ₹96431.29₹96431.29 | 26.19Average 26.2 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2098.30₹2098 | ₹95944.77₹95944.77 | 17.34Average 17.3 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.40₹1145 | ₹95640.90₹95640.90 | 29.60Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2269.50₹2270 | ₹93730.35₹93730.35 | 45.86Average 45.9 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price448453.16 Cr
- Divi's Laboratories Limited share price250703.25 Cr
- Torrent Pharmaceuticals Limited share price167266.93 Cr
- Zydus Lifesciences Limited share price112833.88 Cr
- Cipla Limited share price110732.00 Cr
NGL Fine-Chem Limited PE Ratio History
Historical price-to-earnings ratio for NGLFINE — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹34.19 | ₹1406.20 | 41.1x |
| FY 2024 | ₹66.88 | ₹1811.15 | 27.1x |
| FY 2023 | ₹33.18 | ₹2230.45 | 67.2x |
| FY 2022 | ₹80.77 | ₹1536.10 | 19x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
NGL Fine-Chem Limited Dividend History
Annual cash dividends paid by NGLFINE — dividend yield 0.06%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹1.08 Cr |
| FY 2024 | ₹1.08 Cr |
| FY 2023 | ₹1.08 Cr |
| FY 2022 | ₹1.08 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
NGL Fine-Chem Limited Quarterly Performance
Latest quarterly metrics for NGLFINE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
33.57%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
2282.69%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
13.62%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-5.58%
Compounded annual net profit growth over 5 years
NGL Fine-Chem Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for NGLFINE — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
NGL Fine-Chem Limited Financial Statements
Annual income statement, balance sheet and cash flow for NGL Fine-Chem Limited (NGLFINE) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for NGL Fine-Chem Limited
About NGLFINE (NGL Fine-Chem Limited)
NGL Fine Chem Ltd is a dynamic player in the pharmaceutical landscape, specializing in the development and manufacturing of high-quality active pharmaceutical ingredients (APIs) an...d advanced intermediates. With a strong emphasis on innovation, NGLFINE caters to both the veterinary and human health sectors, serving as a reliable partner for pharmaceutical companies worldwide. The company's commitment to rigorous quality standards and cutting-edge technology ensures the consistent production of safe and effective products, contributing to improved health outcomes for both animals and humans. NGLFINE operates with a global perspective, serving clients across diverse markets through strategic partnerships and a robust supply chain network. NGLFINE distinguishes itself through a comprehensive portfolio of specialized APIs tailored to address critical health needs. In the veterinary arena, NGLFINE offers a range of antiparasitic and therapeutic compounds designed to combat common animal ailments, enhancing livestock health and productivity. For human health applications, NGLFINE provides crucial ingredients for a variety of pharmaceutical formulations, focusing on areas where unmet needs exist. The company's focus extends beyond manufacturing, as it actively invests in research and development to expand its product offerings and explore novel therapeutic solutions. This dedication to innovation positions NGLFINE at the forefront of the pharmaceutical industry, driving advancements in healthcare. NGLFINE is deeply committed to environmental sustainability and ethical business practices. The company operates with a responsible approach, implementing measures to minimize environmental impact throughout its manufacturing processes. By adhering to stringent regulatory guidelines and prioritizing workplace safety, NGLFINE fosters a culture of integrity and accountability. This commitment extends to its relationships with customers, suppliers, and the communities in which it operates, fostering trust and long-term partnerships. NGLFINE's dedication to quality, innovation, and sustainability underscores its mission to improve global health while operating responsibly.
Company Details
Key Leadership
NGLFINE Share Price: Frequently Asked Questions
What is the current share price of NGL Fine-Chem Limited?
NGL Fine-Chem Limited (NGLFINE) trades at ₹2673.80 on NSE and BSE. Market cap ₹1.65K (Cr). Educational data only.
What is the P/E ratio of NGL Fine-Chem Limited?
NGL Fine-Chem Limited has a P/E of 28.88x vs industry average 34.89x.
What is the Bull Run score for NGL Fine-Chem Limited?
NGL Fine-Chem Limited has a Bull Run score of 49.3/100 based on 25+ financial parameters.
Does NGL Fine-Chem Limited pay dividends?
NGL Fine-Chem Limited has a dividend yield of 0.06%. Past dividends don't guarantee future payments.
What is the ROE of NGL Fine-Chem Limited?
NGL Fine-Chem Limited has ROE of 0.00%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of NGL Fine-Chem Limited?
NGL Fine-Chem Limited has debt-to-equity of 0.33.
Is NGL Fine-Chem Limited a good investment?
Bull Run gives NGL Fine-Chem Limited a score of 49.3/100. This is not investment advice — consult a SEBI-registered advisor.